Joseph V. Simone, MD, of the Simone Consulting Company, gives his expert perspective on the important messages of this year’s meeting.
Rogerio Lilenbaum, MD, of Yale Cancer Center/Smilow Cancer Hospital, discusses the importance of tumor profiling for non–small cell lung cancer and strategies for treating EGFR-positive disease in the first-line setting.
Alan Venook, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses new observations on biomarkers, the best combinations of therapies, and how to sequence them.
Kevin C. Oeffinger, MD, of Memorial Sloan Kettering Cancer Center, discusses American Cancer Society recommendations, including the advice that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45, and that women 55 and older should have biennial screening.
Jeffrey Jones, MD, MPH, of the Ohio State University Comprehensive Cancer Center, discusses the use of small molecule inhibitors in developing an individualized treatment plan for patients with CLL.
Douglas E. Wood, MD, of the University of Washington, discusses important new developments in early detection, the need to educate primary care physicians and patients, and the potential to save up to 15,000 lives each year.
